Delivering flexibility and assurance, our model supports mid-market and global pharma partners with tailored solutions that scale seamlessly without compromising compliance.
By integrating our design consultancy and clean-room manufacturing under one ecosystem, this model aims to accelerate the development of combination products by reducing hand-offs and preserving tacit knowledge.
You can read the full article by European Pharmaceutical Review here. But here are the key take aways:
- The model brings together design and manufacturing under a single brand and governance structure, intended to shorten development timelines and reduce risk.
- It is a response to structural shifts in the pharmaceutical industry: growth in biologics, biosimilars, rare disease programs, and specialized delivery formats, which demand flexible, small-to-mid volume, high-mix manufacturing.
- Our teams now co-develop user requirements, tooling, assembly, cleaning and test constraints at the outset of a project, combining human-centered design with engineering and digitized workflows.
- Ensera operates a global footprint (North America, Europe, Southeast Asia), with investments in pharma-grade cleanroom capacity and design studios, underpinned by standardized digital systems to support regulatory consistency and knowledge transfer.
- Our services are perfect for mid-market innovators and specialized programs within pharmaceutical companies who need tailored processes and scalable capacity without compromising on compliance.
